Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma.
BACKGROUND Nivolumab-relatlimab, a dual immune checkpoint inhibitor targeting PD-1 and LAG-3, has demonstrated improved outcomes compared with nivolumab monotherapy in previously untreated advanced melanoma. However, real-world data in broader and less selected populations remain limited. METHODS We conducted a multi...